A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Intended for UK patients and members of the public

SmPC- Hapoctasin 52.5 microgram/h, Transdermal Patches: Change history

Back to products

View Summary of Product Characteristics (SmPC- Hapoctasin 52.5 microgram/h, Transdermal Patches)

Last updated on this site: 10 Apr 2025

To update section 4.4 of the SmPC and the PIL in line with the MHRA request regarding prolonged-release opioids (to include OIVI and PPOU warnings).

View change history

Changes: (Updated: 10 Apr 2025)

To update section 4.4 of the SmPC and the PIL in line with the MHRA request regarding prolonged-release opioids (to include OIVI and PPOU warnings).
Changes: (Updated: 25 Nov 2024)

IB, C.I.3.z - Adjustment of SPC and PIL according to PSUSA/00000459/202309 - buprenorphine (all formulations except implants)
Changes: (Updated: 20 Sep 2022)

Initial upload